Nu Skin Reports First Quarter Revenue at High End of Guidance
Nu Skin (NYSE: NUS) announced first quarter revenue at the high end of its guidance range.
Executive Summary: Q1 2025 vs. Prior-year Quarter
|
Revenue |
$364.5 million; (12.7)% (3.0)% FX impact or $(12.3) million |
|
Earnings Per Share |
$2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges |
|
Customers |
776,712; (11)% |
|
Paid Affiliates |
131,518; (15)% |
|
Sales Leaders |
31,036; (20)% |
“We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year,”
Ryan Napierski, Nu Skin president and CEO said.
“We drove year-over-year growth in Latin America and our Rhyz manufacturing segment, but we continue to experience consumer caution in premium beauty due to concerns such as inflation and tariffs in many parts of the world. Through 2025, we remain focused on building on our recent product launches and preparing for the preview of our Prysm iO intelligent wellness device in the back half of the year. This palm-sized device provides real-time insights into a customer’s health, informing recommendations for product subscriptions and increasing customer satisfaction and loyalty. We are also laying the groundwork for expansion into India with a market pre-opening in Q4 and formal launch in mid-2026 and prioritizing our efforts to continue improving margins across the board.”
Q1 2025 Year-Over-Year Operating Results
|
Revenue |
$364.5 million compared to $417.3 million (3.0)% FX impact or $(12.3) million |
|
Gross Margin |
67.8% compared to 70.5% Nu Skin business was 76.7% compared to 76.9% |
|
Selling Expenses |
32.5% compared to 36.8% Nu Skin business was 38.7% compared to 41.7% |
|
G&A Expenses |
31.1% or 28.9% excluding certain charges compared to 29.9% |
|
Restructuring and |
$25.1 million impairment compared to $7.3 million restructuring charges |
|
Operating Margin |
(2.7)% or 6.4% excluding impairment and other charges compared to 2.1% or 3.8% excluding restructuring charges |
|
Interest Expense |
$3.3 million compared to $7.3 million |
|
Gain on Sale of |
$176.2 million gain on sale of Mavely |
|
Other Expense |
$28.4 million compared to $0.4 million Reflects $28.1 million unrealized loss on investment |
|
Income Tax Rate |
20.1% or 41.9% excluding Mavely gain and other charges compared to 148.4% or 48.5% excluding restructuring charges |
|
EPS |
$2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges |
Stockholder Value
|
Dividend Payments |
$3.0 million |
|
Stock Repurchases |
$5.0 million $157.4 million remaining in authorization |
Q2 and Full-year 2025 Outlook
|
Q2 2025 Revenue |
$355 to $390 million; (19)% to (11)% or (17)% to (9)% excluding Mavely 2024 revenue Approximately (3) to (2)% FX impact |
|
Q2 2025 EPS |
$0.20 to $0.30 |
|
2025 Revenue |
$1.48 to $1.62 billion; (15)% to (6)% or (11)% to (3)% excluding Mavely 2024 revenue Approximately (3)% FX impact |
|
2025 EPS |
$2.80 to $3.20 or $0.90 to $1.30 excluding Mavely gain and other charges |
“In addition to delivering on revenue and adjusted earnings, we saw encouraging improvement in core Nu Skin operating margin, driven by ongoing cost efficiency initiatives across every segment,”
said James D. Thomas, chief financial officer.
“We also made meaningful progress in strengthening our balance sheet by reducing outstanding debt by $155 million, achieving our lowest debt level in more than 10 years. In addition, we returned $8 million to shareholders — $3 million in the form of dividends and $5 million via share repurchases. While macroeconomic uncertainty around trade tensions and tariffs continues to impact visibility, we are maintaining our adjusted annual guidance as we closely monitor developments throughout the remainder of 2025. For the second quarter, we project revenue between $355 million and $390 million, with earnings per share in the range of $0.20 to $0.30.”
About Nu Skin Enterprises Inc.
The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company’s products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.
Get more information, facts and figures about Nu Skin, click here for the Nu Skin overview.